Relacorilant in Combination With Nab-Paclitaxel in Advanced, Platinum-Resistant, High-Grade Epithelial Ovarian, Primary Peritoneal, or Fallopian-Tube Cancer
Clinical trial NCT05257408 · ACTIVE_NOT_RECRUITING
Trial details
- NCT number
- NCT05257408
- Sponsor
- Corcept Therapeutics
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- Phase 3
- Study type
- INTERVENTIONAL
- Start date
- 2022-06-29
- Primary completion
- 2025-03-24
- Enrollment
- 381
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.